The Value of Cefoperazone Sulbactam and Amiloride Hydrochloride in the Treatment of Chronic Obstructive Pulmonary Disease

  • Rong Fan Jingzhou First People's Hospital
  • Wei Xiao Jingzhou First People's Hospital
  • Weihua Hu Jingzhou First People's Hospital
  • Zhu Wu Jingzhou First People's Hospital
DOI: https://doi.org/10.18686/aem.v12i1.348
Keywords: Chronic Obstructive Pulmonary Disease, Cefoperazone Sulbactam, Ambroxol Hydrochloride, Effect Observation

Abstract

Objective: To observe the effect of different drug regimens in the treatment of chronic obstructive pulmonary disease (COPD). Methods: Sixty-two patients with COPD admitted from 2020.9 to 2022.12 were divided into two equal groups, group A and group B. Thirty-two patients each were treated with cefoperazone sulbactam, while group B was treated with ambroxol hydrochloride. Results: The total effective rate in Group B reached 93.55%, higher than 67.74% in Group A (X²=5.063, P=0.024<0.05). The time to disappearance of disease symptoms and hospital stay were shorter in Group B than in Group A. The difference reached a significant level (P < 0.05). Conclusion: Clinical treatment of COPD patients with amiloride hydrochloride combined with cefoperazone sulbactam as early as possible is effective and worth promoting.

References

[1] Peng GR, Wang SP. Correlation between sputum pathogenic bacteria analysis and BODE index in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Journal of Clinical Pulmonology,2021,26(09):1356-1359.

[2] He XP. Effect of nebulized inhalation of ambroxol hydrochloride on acute exacerbation of chronic obstructive pulmonary disease[J]. China Urban and Rural Enterprise Health,2022,37(01):131-132.

[3] Sun GH. Analysis of antimicrobial drug treatment during acute exacerbation of chronic obstructive pulmonary disease[J]. Electronic journal of clinical medicine literature,2019,6(93):63.
Published
2023-03-21
Issue
Vol 12, No 1(2023)
Section
Original Research Article

Copyright (c) 2023 Rong Fan, Wei Xiao, Weihua Hu, Zhu Wu

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.